Literature DB >> 26011265

Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial.

Gennaro Sardella1, Simone Calcagno2, Massimo Mancone2, Luigi Lucisano2, Mauro Pennacchi2, Rocco Edoardo Stio2, Filippo Placentino2, Angelo Di Roma2, Erika Cavallo2, Raffaele Palmirotta3, Fiorella Guadagni3, Francesco Fedele2.   

Abstract

Entities:  

Keywords:  Clopidogrel; Genetics; High on-treatment platelet reactivity; Prasugrel; Stable coronary artery disease; Ticagrelor

Mesh:

Substances:

Year:  2015        PMID: 26011265     DOI: 10.1016/j.ijcard.2015.05.085

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  3 in total

1.  Comment on "Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions".

Authors:  Ramachandra Barik; Lalita Nemani
Journal:  Indian Heart J       Date:  2015-10-26

2.  Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.

Authors:  Dingyu Zhang; Xiaolin Zhang; Dan Liu; Tengfei Liu; Wenzhi Cai; Chenghui Yan; Yaling Han
Journal:  Cardiovasc Diabetol       Date:  2016-03-22       Impact factor: 9.951

3.  Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.

Authors:  Mingxiang Wen; Yaqi Li; Xiang Qu; Yanyan Zhu; Lingfang Tian; Zhongqin Shen; Xiulin Yang; Xianqing Shi
Journal:  BMC Cardiovasc Disord       Date:  2020-10-01       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.